H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Revance to $41 from $48 and keeps a Buy rating on the shares post the Q2 report. While early, Daxxify is showing good traction, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RVNC:
- 3 Best Stocks to Buy Now, 8/9/2023, According to Top Analysts
- Revance sees FY23 adjusted operating expenses $320M-$340M
- Revance Therapeutics reports Q2 EPS (80c), consensus (78c)
- Cantor biotech/biopharma analysts to hold analyst/industry conference call
- Revance Therapeutics (RVNC) Q2 Earnings Cheat Sheet